New pharma tariffs are pushing biotech firms to consider voluntary pricing deals with the Trump administration for exemptions, Axios reports
- Smaller and midsize companies say they lack the scale and financial flexibility of larger drugmakers to cut prices or reshore production, while carveouts for orphan drugs and cell and gene therapies may soften the impact for some.
Context
The report on new pharma tariffs indicates a significant trade development that could lead to voluntary pricing agreements between biotech firms and the Trump administration. This situation is particularly pressing for smaller and midsize companies, as they may struggle with the financial impact compared to larger players. Investors should monitor how these negotiations could influence biotech stock valuations and broader market sentiment in the healthcare sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#FOREX#EQUITIES#ENERGY#EU SESSION#WTI#COMMODITIES#DXY#TRUMP#TRADE